Human TAN and PMN-MDSC protumor and antitumor functions
| . | TANs/PMN-MDSCs . | Reference . | T-cell suppression confirmed in humans . | |
|---|---|---|---|---|
| TANs . | PMN-MDSCs . | |||
| Protumor | ||||
| T/NK cell suppression | ||||
| Arginase 1 | TANs, PMN-MDSCs | 59 | 74,82,-84,91 | Yes |
| ROS | TANs, PMN-MDSCs | 92 | 84,85 | No |
| STAT3 | PMN-MDSCs | 93 | Yes | |
| STAT/IRF-8 | PMN-MDSCs | 78 | No | |
| LOX-1 | PMN-MDSCs | 89,90 | Yes | |
| mPR3 | TANs | 61 | N/A | |
| MPO/hydrogen peroxide | TANs | 62,63 | N/A | |
| Angiogenesis/metastasis | ||||
| VEGF | TANs, PMN-MDSCs | 94 | 83 | Yes |
| MMP9 | TANs, PMN-MDSCs | 34,95 | 88 | Yes |
| NAMPT/STAT3 | TANs | 36 | N/A | |
| Oncostatin M | TANs | 45,46 | N/A | |
| NETs | TANs | 38 | N/A | |
| TNF-α | TANs | 55 | N/A | |
| IL-8 | TANs | 43,44,59 | N/A | |
| Elastase | TANs | 37 | N/A | |
| Immune cell recruitment | ||||
| CCL17 | TANs | 39,40 | N/A | |
| CCL2 | TANs | 39 | N/A | |
| Antitumor | ||||
| Tumor cytotoxicity | ||||
| ROS | TAN | 30,96 | N/A | |
| Granzyme B | TAN | 97 | N/A | |
| MET signaling | TAN | 32 | N/A | |
| Trogoptosis | TAN | 52 | N/A | |
| TNF-α | TAN | 32,53 | N/A | |
| T-cell activation/priming | ||||
| Mechanism unknown | TAN | 48,98 | N/A | |
| NETs | TAN | 49 | N/A | |
| . | TANs/PMN-MDSCs . | Reference . | T-cell suppression confirmed in humans . | |
|---|---|---|---|---|
| TANs . | PMN-MDSCs . | |||
| Protumor | ||||
| T/NK cell suppression | ||||
| Arginase 1 | TANs, PMN-MDSCs | 59 | 74,82,-84,91 | Yes |
| ROS | TANs, PMN-MDSCs | 92 | 84,85 | No |
| STAT3 | PMN-MDSCs | 93 | Yes | |
| STAT/IRF-8 | PMN-MDSCs | 78 | No | |
| LOX-1 | PMN-MDSCs | 89,90 | Yes | |
| mPR3 | TANs | 61 | N/A | |
| MPO/hydrogen peroxide | TANs | 62,63 | N/A | |
| Angiogenesis/metastasis | ||||
| VEGF | TANs, PMN-MDSCs | 94 | 83 | Yes |
| MMP9 | TANs, PMN-MDSCs | 34,95 | 88 | Yes |
| NAMPT/STAT3 | TANs | 36 | N/A | |
| Oncostatin M | TANs | 45,46 | N/A | |
| NETs | TANs | 38 | N/A | |
| TNF-α | TANs | 55 | N/A | |
| IL-8 | TANs | 43,44,59 | N/A | |
| Elastase | TANs | 37 | N/A | |
| Immune cell recruitment | ||||
| CCL17 | TANs | 39,40 | N/A | |
| CCL2 | TANs | 39 | N/A | |
| Antitumor | ||||
| Tumor cytotoxicity | ||||
| ROS | TAN | 30,96 | N/A | |
| Granzyme B | TAN | 97 | N/A | |
| MET signaling | TAN | 32 | N/A | |
| Trogoptosis | TAN | 52 | N/A | |
| TNF-α | TAN | 32,53 | N/A | |
| T-cell activation/priming | ||||
| Mechanism unknown | TAN | 48,98 | N/A | |
| NETs | TAN | 49 | N/A | |
LOX-1, low-density lipoprotein receptor-1; mPR3, membrane-associated proteinase 3; N/A, not applicable; NAMPT, nicotinamide phosphoribosyltransferase; NET, neutrophil extracellular trap; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor α; VEGF, vascular endothelial growth factor.